Atara Biotherapeutics (ATRA) Expected to Announce Earnings on Wednesday

Atara Biotherapeutics (NASDAQ:ATRA) is expected to post its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Atara Biotherapeutics to announce earnings of ($0.1328) per share and revenue of $0.80 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). The business had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $0.55 million. On average, analysts expect Atara Biotherapeutics to post ($0.22) EPS for the current fiscal year and $1.38 EPS for the next fiscal year.

Atara Biotherapeutics Trading Down 2.7%

NASDAQ:ATRA opened at $8.25 on Wednesday. The company has a market cap of $82.83 million, a price-to-earnings ratio of -6.99 and a beta of 0.28. Atara Biotherapeutics has a twelve month low of $3.92 and a twelve month high of $19.15. The stock has a fifty day simple moving average of $9.15 and a 200-day simple moving average of $7.71.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wall Street Zen raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Weiss Ratings raised shares of Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Insider Buying and Selling at Atara Biotherapeutics

In other Atara Biotherapeutics news, Director Brian N. Cherry bought 104,166 shares of the company’s stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $9.60 per share, for a total transaction of $999,993.60. Following the acquisition, the director directly owned 166,486 shares in the company, valued at approximately $1,598,265.60. The trade was a 167.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Anhco Nguyen sold 5,062 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $8.08, for a total transaction of $40,900.96. Following the transaction, the chief executive officer directly owned 132,775 shares in the company, valued at $1,072,822. This trade represents a 3.67% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 41.20% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics is a biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and serious diseases associated with Epstein-Barr virus (EBV). The company’s platform uses donor-derived, virus-specific T cells that are designed to recognize and eliminate infected or malignant cells without requiring cells to be collected from each individual patient.

Atara’s lead product, tabelecleucel, is marketed in the European Union under the brand name Ebvallo.